Form 4: Ionis Pharma CSO Sells Shares After Option Exercise
Insider Transaction Report
Ionis Pharmaceuticals' Chief Scientific Officer, C. Frank Bennett, executed planned sales of common stock following the exercise of stock options.
Summary
- C. Frank Bennett, EVP, Chief Scientific Officer of IONIS PHARMACEUTICALS INC, engaged in multiple transactions involving the company's common stock.
- On September 2, 2025, 5,000 shares of common stock were sold at a price of $49.14 per share.
- On September 3, 2025, 46,800 shares were acquired through the exercise of non-qualified stock options at an exercise price of $53.77 per share.
- Also on September 3, 2025, 33,909 shares were sold at a weighted average price of $60.62 per share, with individual transaction prices ranging from $60.25 to $61.24.
- Additionally, on September 3, 2025, 12,891 shares were sold at a weighted average price of $61.50 per share, with individual transaction prices ranging from $61.26 to $61.995.
- All sales were conducted pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 13, 2025.
- Following these reported transactions, direct beneficial ownership of common stock for C. Frank Bennett stands at 88,679 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While there was a net sale of shares by an executive, it was conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling. The exercise of options is a positive for the executive, reflecting a realization of compensation.
Positives
- The Chief Scientific Officer exercised stock options, indicating personal financial benefit from company performance and a vested interest in the company's long-term success.
- All reported sales were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned and non-discretionary disposition of shares, mitigating concerns about opportunistic selling.
Negatives
- A net total of 5,000 shares were disposed of by a key executive (51,800 shares sold versus 46,800 shares acquired), resulting in a slight reduction in direct beneficial ownership.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may observe a slight reduction in executive ownership, though the planned nature of the transactions under a 10b5-1 plan lessens potential negative interpretations regarding management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2020-01-02 | Date non-qualified stock options became exercisable. |
| 2025-01-01 | Expiration date of non-qualified stock options. |
| 2025-05-13 | Date Rule 10b5-1 Trading Plan was adopted by the reporting person. |
| 2025-09-02 | Date of common stock sale transaction. |
| 2025-09-03 | Date of non-qualified stock option exercise and subsequent common stock sales. |
| 2025-09-04 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThe filing details routine insider transactions, specifically the exercise of stock options and subsequent sales, all conducted under a pre-established Rule 10b5-1 trading plan. These transactions do not reflect a change in the company's fundamental prospects or new material information, thus a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment thesis based solely on this filing.
Keywords
Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Executive Compensation, C. Frank Bennett, Rule 10b5-1, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.